Product Description
Mechanisms of Action: PfATP6 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: India
Approved Indications: None
Known Adverse Events: None
Company: University of Oxford
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Malaria, Falciparum
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| TACTKenya | P3 |
Completed |
Malaria, Falciparum |
2019-06-03 |
2024-06-28 |
||
| BAKMAL1501 | P3 |
Withdrawn |
Malaria, Falciparum |
2017-06-01 |
2019-03-20 |
Treatments |
|
| RBx/MMV05-06 | P2 |
Completed |
Malaria, Falciparum |
None |
2019-03-21 |
Treatments |